United States: Induced Infringement Of Method Of Treatment Claims: Does "United We Stand, Divided We Fall" Really Apply?

Method of treatment claims have long been part of the pharmaceutical industry's patent portfolio to protect its innovative drug products. Many such method claims, however, were drafted long ago and may arguably require more than one actor to complete all of the recited steps, a problem called "divided infringement." In 2014, the U.S. Supreme Court held in Limelight Networks, Inc. v. Akamai Technologies, Inc., 134 S. Ct. 2111, that a single entity must perform all steps of the claimed method to give rise to liability for induced infringement. This created a new issue for pharmaceutical patent litigants—could method of treatment claims be avoided simply by arguing that the steps required actions by both healthcare providers and patients? Decisions such as Endo v. Amneal, 2015 BL 279190 (S.D.N.Y. Aug. 18, 2015), where ANDA filers were not held liable for inducement of method of treatment claims requiring healthcare providers to "provide" a claimed drug product and patients to "administer" it, seemed to support that view.

Perhaps recognizing this potential issue with divided infringement, which certainly spills over to other industries as well, the Supreme Court remanded the Limelight case to the Federal Circuit to reconsider the standard for direct infringement. There the Federal Circuit held en banc that one could be liable for direct infringement even if more than one actor performs all of the claimed method steps, if "the acts of one are attributable to the other such that a single entity is responsible for the infringement." Akamai Techs., Inc. v. Limelight Networks, Inc., 797 F.3d 1020, 1022 (Fed. Cir. 2015). The acts could be attributable to a single entity when that entity directs or controls the other's performance, or if the actors formed a joint enterprise. Id.

What remained was to see how this would play out in the context of ANDA litigation involving pharmaceutical method of treatment claims. Could one combine Limelight and Akamai such that an ANDA filer could be liable for inducing direct infringement by a healthcare provider who performed at least one method step and then directed or controlled the performance of the remaining method steps by another person, e.g., a patient, diagnostic laboratory, or another physician? In other words, could Limelight inducement be predicated on Akamai direct, divided infringement in the context of method of treatment claims in ANDA cases?

With respect to a challenge to induced infringement on the basis of divided infringement, Judge Andrews of the District of Delaware provided hope to patentees, speculating: "Although the issue is not presently before the Court, I am dubious as to whether Defendant's [defense based on a divided infringement theory] will be successful in light of the Federal Circuit's en banc decision in Akamai . . . ." Takeda Pharm. Co. Ltd. v. Actavis Labs. FL, Inc., No. CV 15-451-RGA, 2016 BL 179558, n.4 (D. Del. June 6, 2016) (noting, however, that the issue "is properly a question for another day").

Recently, the Federal Circuit decided this issue in Eli Lilly & Co. v. Teva Parenteral Medicines, Inc., 845 F.3d 1357 (Fed. Cir. 2017), on appeal from the Southern District of Indiana. The patent at issue was directed to methods of administering pemetrexed disodium, a chemotherapy drug, after the patients had been premedicated with two vitamins, folic acid and vitamin B12. All of the method claims at issue required patient pretreatment by "administering" or "administration of" folic acid, followed by chemotherapeutic treatment with pemetrexed disodium. Id. at 1362. The parties had agreed that physicians gave patients the vitamin B12 and pemetrexed, but that patients self-administered the folic acid in accordance with guidance from the physician, and thus no one single actor performed all claimed method steps. Id.

In the face of a clear case of divided infringement, the Lilly decision applied the "directs or controls" standard for direct infringement that had been articulated in its en banc Akamai decision: one must (1) condition participation in an activity or receipt of a benefit upon others' performance of one or more steps of the patented method, and (2) establish the manner or timing of that performance. Id. at 1365. Holding that the relevant benefit is pemetrexed treatment, the Court held that substantial evidence supported the district court's finding that physicians condition receipt of the benefit of pemetrexed treatment on the administration of folic acid by the patient. Id. at 1366. Indeed, the Federal Circuit pointed to the product labeling, noting that folic acid is a requirement for premedication, and to evidence that a physician would refuse to give pemetrexed unless the patient had undergone the folic acid pretreatment. Id. Furthermore, the Federal Circuit rejected the arguments that "conditioning" could only be shown by imposing a legal obligation to perform the folic acid step, or by "interposing that step as an unavoidable technological prerequisite to participation." Id. at 1366-1367 (citations and quotations omitted). The Federal Circuit also rejected arguments that physicians needed to verify patients' compliance or to threaten the denial of potentially life-saving treatment. Id.

As for the second prong of the "directs or controls" test, the Federal Circuit again turned to the product labeling and expert testimony to support the district court's finding that the physician established the manner or timing—both dosage and time frame—of the folic acid pretreatment. Id. at 1367. The court was careful to point out, however, that its holding "does not assume that patient action is attributable to a prescribing physician solely because they have a physician-patient relationship." Id.

The foregoing analysis was sufficient to establish direct infringement under the Akamai standard, but what remained was the question of inducement by the ANDA filer. There, the Federal Circuit once again examined the proposed ANDA product's labeling and found "repeated instructions and warnings regarding the importance of and reasons for folic acid treatment" that are directed at physicians and that encourage or recommend infringement. Id. at 1369. As such, the Court held that while both physicians and patients were the direct infringers, the ANDA filer was liable for inducing infringement by the physicians. Even though some physicians might not adhere to the labeling's instructions and warnings, the proposed product labeling would inevitably lead at least some physicians to infringe the claimed methods, which suffices for establishing the requisite intent for inducement. Id. The Court also gave no weight to the fact that physicians may take steps beyond the instructions in the product labeling, finding their "decision to give patients even more specific guidance
is irrelevant to the question of inducement." Id.

The Federal Circuit affirmed the holding of induced infringement in the Lilly case, which bodes well for enforcement of method claims that fall within the scope of the test laid out in Akamai. Of course, it may be prudent to now draft method claims that might avoid the level of additional proof needed to survive the Akamai test for divided infringement, particularly for drugs unlike pemetrexed that do not so steadfastly require the action of two entities. The Lilly case also shows the importance, when possible, of drafting method claims grounded in the text of the product labeling to more easily survive the inducement inquiry. It remains to be seen how courts will address charges of pharmaceutical method claim inducement in the context of other situations involving divided infringement, or perhaps if reliance on contributory infringement theories may increase for post-Akamai infringement of method claims.

Previously published in BNA Pharmaceutical Law and Industry Report

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

To print this article, all you need is to be registered on Mondaq.com.

Click to Login as an existing user or Register so you can print this article.

Authors
Events from this Firm
24 Jul 2018, Webinar, Washington, DC, United States

The program will consider arguments that have worked to avoid a finding of inequitable conduct or unclean hands and those that have not been successful.

9 Aug 2018, Webinar, Washington, DC, United States

As part of Strafford Publications’ webinar series, Finnegan partners Shana Cyr and Barbara Rudolph will discuss best practices for patent counsel navigating the 30-month stay in Hatch-Waxman Act litigation.

5 Sep 2018, Webinar, Washington, DC, United States

Finnegan’s 2018 webinar series addresses challenges across the IP landscape in the United States. The series starts with one of the fundamentals—proving or disproving obviousness. The panelists will address what works and what doesn’t before U.S. Patent and Trademark Office (USPTO) examiners, before the Patent Trial and Appeal Board (PTAB), and before the courts.

Similar Articles
Relevancy Powered by MondaqAI
 
In association with
Related Topics
 
Similar Articles
Relevancy Powered by MondaqAI
Related Articles
 
Related Video
Up-coming Events Search
Tools
Print
Font Size:
Translation
Channels
Mondaq on Twitter
 
Register for Access and our Free Biweekly Alert for
This service is completely free. Access 250,000 archived articles from 100+ countries and get a personalised email twice a week covering developments (and yes, our lawyers like to think you’ve read our Disclaimer).
 
Email Address
Company Name
Password
Confirm Password
Position
Mondaq Topics -- Select your Interests
 Accounting
 Anti-trust
 Commercial
 Compliance
 Consumer
 Criminal
 Employment
 Energy
 Environment
 Family
 Finance
 Government
 Healthcare
 Immigration
 Insolvency
 Insurance
 International
 IP
 Law Performance
 Law Practice
 Litigation
 Media & IT
 Privacy
 Real Estate
 Strategy
 Tax
 Technology
 Transport
 Wealth Mgt
Regions
Africa
Asia
Asia Pacific
Australasia
Canada
Caribbean
Europe
European Union
Latin America
Middle East
U.K.
United States
Worldwide Updates
Registration (you must scroll down to set your data preferences)

Mondaq Ltd requires you to register and provide information that personally identifies you, including your content preferences, for three primary purposes (full details of Mondaq’s use of your personal data can be found in our Privacy and Cookies Notice):

  • To allow you to personalize the Mondaq websites you are visiting to show content ("Content") relevant to your interests.
  • To enable features such as password reminder, news alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
  • To produce demographic feedback for our content providers ("Contributors") who contribute Content for free for your use.

Mondaq hopes that our registered users will support us in maintaining our free to view business model by consenting to our use of your personal data as described below.

Mondaq has a "free to view" business model. Our services are paid for by Contributors in exchange for Mondaq providing them with access to information about who accesses their content. Once personal data is transferred to our Contributors they become a data controller of this personal data. They use it to measure the response that their articles are receiving, as a form of market research. They may also use it to provide Mondaq users with information about their products and services.

Details of each Contributor to which your personal data will be transferred is clearly stated within the Content that you access. For full details of how this Contributor will use your personal data, you should review the Contributor’s own Privacy Notice.

Please indicate your preference below:

Yes, I am happy to support Mondaq in maintaining its free to view business model by agreeing to allow Mondaq to share my personal data with Contributors whose Content I access
No, I do not want Mondaq to share my personal data with Contributors

Also please let us know whether you are happy to receive communications promoting products and services offered by Mondaq:

Yes, I am happy to received promotional communications from Mondaq
No, please do not send me promotional communications from Mondaq
Terms & Conditions

Mondaq.com (the Website) is owned and managed by Mondaq Ltd (Mondaq). Mondaq grants you a non-exclusive, revocable licence to access the Website and associated services, such as the Mondaq News Alerts (Services), subject to and in consideration of your compliance with the following terms and conditions of use (Terms). Your use of the Website and/or Services constitutes your agreement to the Terms. Mondaq may terminate your use of the Website and Services if you are in breach of these Terms or if Mondaq decides to terminate the licence granted hereunder for any reason whatsoever.

Use of www.mondaq.com

To Use Mondaq.com you must be: eighteen (18) years old or over; legally capable of entering into binding contracts; and not in any way prohibited by the applicable law to enter into these Terms in the jurisdiction which you are currently located.

You may use the Website as an unregistered user, however, you are required to register as a user if you wish to read the full text of the Content or to receive the Services.

You may not modify, publish, transmit, transfer or sell, reproduce, create derivative works from, distribute, perform, link, display, or in any way exploit any of the Content, in whole or in part, except as expressly permitted in these Terms or with the prior written consent of Mondaq. You may not use electronic or other means to extract details or information from the Content. Nor shall you extract information about users or Contributors in order to offer them any services or products.

In your use of the Website and/or Services you shall: comply with all applicable laws, regulations, directives and legislations which apply to your Use of the Website and/or Services in whatever country you are physically located including without limitation any and all consumer law, export control laws and regulations; provide to us true, correct and accurate information and promptly inform us in the event that any information that you have provided to us changes or becomes inaccurate; notify Mondaq immediately of any circumstances where you have reason to believe that any Intellectual Property Rights or any other rights of any third party may have been infringed; co-operate with reasonable security or other checks or requests for information made by Mondaq from time to time; and at all times be fully liable for the breach of any of these Terms by a third party using your login details to access the Website and/or Services

however, you shall not: do anything likely to impair, interfere with or damage or cause harm or distress to any persons, or the network; do anything that will infringe any Intellectual Property Rights or other rights of Mondaq or any third party; or use the Website, Services and/or Content otherwise than in accordance with these Terms; use any trade marks or service marks of Mondaq or the Contributors, or do anything which may be seen to take unfair advantage of the reputation and goodwill of Mondaq or the Contributors, or the Website, Services and/or Content.

Mondaq reserves the right, in its sole discretion, to take any action that it deems necessary and appropriate in the event it considers that there is a breach or threatened breach of the Terms.

Mondaq’s Rights and Obligations

Unless otherwise expressly set out to the contrary, nothing in these Terms shall serve to transfer from Mondaq to you, any Intellectual Property Rights owned by and/or licensed to Mondaq and all rights, title and interest in and to such Intellectual Property Rights will remain exclusively with Mondaq and/or its licensors.

Mondaq shall use its reasonable endeavours to make the Website and Services available to you at all times, but we cannot guarantee an uninterrupted and fault free service.

Mondaq reserves the right to make changes to the services and/or the Website or part thereof, from time to time, and we may add, remove, modify and/or vary any elements of features and functionalities of the Website or the services.

Mondaq also reserves the right from time to time to monitor your Use of the Website and/or services.

Disclaimer

The Content is general information only. It is not intended to constitute legal advice or seek to be the complete and comprehensive statement of the law, nor is it intended to address your specific requirements or provide advice on which reliance should be placed. Mondaq and/or its Contributors and other suppliers make no representations about the suitability of the information contained in the Content for any purpose. All Content provided "as is" without warranty of any kind. Mondaq and/or its Contributors and other suppliers hereby exclude and disclaim all representations, warranties or guarantees with regard to the Content, including all implied warranties and conditions of merchantability, fitness for a particular purpose, title and non-infringement. To the maximum extent permitted by law, Mondaq expressly excludes all representations, warranties, obligations, and liabilities arising out of or in connection with all Content. In no event shall Mondaq and/or its respective suppliers be liable for any special, indirect or consequential damages or any damages whatsoever resulting from loss of use, data or profits, whether in an action of contract, negligence or other tortious action, arising out of or in connection with the use of the Content or performance of Mondaq’s Services.

General

Mondaq may alter or amend these Terms by amending them on the Website. By continuing to Use the Services and/or the Website after such amendment, you will be deemed to have accepted any amendment to these Terms.

These Terms shall be governed by and construed in accordance with the laws of England and Wales and you irrevocably submit to the exclusive jurisdiction of the courts of England and Wales to settle any dispute which may arise out of or in connection with these Terms. If you live outside the United Kingdom, English law shall apply only to the extent that English law shall not deprive you of any legal protection accorded in accordance with the law of the place where you are habitually resident ("Local Law"). In the event English law deprives you of any legal protection which is accorded to you under Local Law, then these terms shall be governed by Local Law and any dispute or claim arising out of or in connection with these Terms shall be subject to the non-exclusive jurisdiction of the courts where you are habitually resident.

You may print and keep a copy of these Terms, which form the entire agreement between you and Mondaq and supersede any other communications or advertising in respect of the Service and/or the Website.

No delay in exercising or non-exercise by you and/or Mondaq of any of its rights under or in connection with these Terms shall operate as a waiver or release of each of your or Mondaq’s right. Rather, any such waiver or release must be specifically granted in writing signed by the party granting it.

If any part of these Terms is held unenforceable, that part shall be enforced to the maximum extent permissible so as to give effect to the intent of the parties, and the Terms shall continue in full force and effect.

Mondaq shall not incur any liability to you on account of any loss or damage resulting from any delay or failure to perform all or any part of these Terms if such delay or failure is caused, in whole or in part, by events, occurrences, or causes beyond the control of Mondaq. Such events, occurrences or causes will include, without limitation, acts of God, strikes, lockouts, server and network failure, riots, acts of war, earthquakes, fire and explosions.

By clicking Register you state you have read and agree to our Terms and Conditions